Search

Your search keyword '"Anagnostou, Aikaterini"' showing total 419 results
Start Over Author "Anagnostou, Aikaterini"
419 results on '"Anagnostou, Aikaterini"'

2. A Review of Shared Decision-Making, Published Protocols, and Post-desensitization Strategies in Oral Immunotherapy (OIT).

Author

Kim, Edwin, Greenhawt, Matthew, Bailey, Sally, Anagnostou, Aikaterini, and Laubach, Susan

Subjects
Dose escalation, Food allergy, Maintenance therapy, Oral immunotherapy, Shared decision-making, Humans, Animals, Desensitization, Immunologic, Administration, Oral, Food Hypersensitivity, Allergens, Milk
Abstract

PURPOSE OF REVIEW: The aim of this review is to highlight key published oral immunotherapy (OIT) protocols and post-desensitization strategies for the major food allergens and to cover important concepts to consider when evaluating OIT for food-allergic patients. Shared decision-making should help identify patient and family values which will help influence the type of evidence-based protocol and maintenance strategy to use. RECENT FINDINGS: With food OIT emerging as a treatment option, there is a pressing need for patients, physicians, and other providers to have a nuanced understanding of the management choices available to them. There are now randomized controlled trials (RCT) of OIT for peanut, egg, milk, and wheat, and reports of cohorts of patients who have undergone OIT for tree nuts and sesame clinically. The current published protocols contain significant diversity in terms of starting dose, build-up schedule, maintenance dose, and even the product used for desensitization. Emerging data can help direct the long-term maintenance strategy for patients on OIT. Based on patient and family values elicited through the shared decision-making process, an OIT protocol may be selected that balances the level of desensitization, potential side effects, frequency of clinic visits, and potential to induce sustained unresponsiveness, among other factors. Once maintenance dosing is reached, most patients will need to maintain regular exposure to the food allergen to remain desensitized. The option to transition to commercial food products with equivalent amounts of food protein as the OIT maintenance dose would simplify the dosing process and perhaps improve palatability as well. Less frequent or decreased OIT dosing can provide practical benefits but may affect the level of desensitization and safety for some patients.

Published
2024

8. Qualitative interviews to understand health care providers experiences of prescribing licensed peanut oral immunotherapy.

Author

Anagnostou, Aikaterini, Lawrence, Claire, Tilles, Stephen, Laubach, Susan, Donelson, Sarah, Yassine, Mohamed, and Nowak-Wegrzyn, Anna

Subjects
Desensitization, Food allergy treatment, Oral immunotherapy, Palforzia, Peanut allergy, Peanut oral immunotherapy, Administration, Oral, Allergens, Arachis, COVID-19, Desensitization, Immunologic, Health Personnel, Humans, Immunologic Factors, Pandemics, Peanut Hypersensitivity, United States
Abstract

OBJECTIVE: This research sought to explore health care providers (HCPs) experiences of delivering the first US Food and Drug Administration (FDA) and European Commission (EC) approved peanut oral immunotherapy (peanut OIT; Palforzia). Semi-structured qualitative interviews with HCPs who had initiated treatment with ≥ 3 patients in the first nine months following FDA approval sought to identify challenges faced and successful implementation strategies. RESULTS: Eight allergists and three nurse practitioners from eight sites based in the United States participated. The HCPs included in this research were motivated to implement this novel treatment, however, entered the process with some reservations. HCPs described how successful implementation of peanut OIT requires them to be thoughtful about their clinics abilities to integrate complex, time-consuming treatments into their daily practice. Prior experience of OIT was deemed beneficial, but not essential for implementation and learning from others experience was suggested as a way of helping new prescribers overcome perceived and actual implementation challenges. Delivering licensed peanut OIT during the COVID-19 pandemic posed both challenges and unexpected opportunities for implementation. The experiences described have the potential to benefit the wider allergy community by providing practical solutions, successful implementation strategies and opportunities to enhance training and resources.

Published
2022

11. Allergic Diseases and Mental Health

Author

Conway, Alexandra E., Verdi, Marylee, Kartha, Navya, Maddukuri, Chaitanya, Anagnostou, Aikaterini, Abrams, Elissa M., Bansal, Priya, Bukstein, Don, Nowak-Wegrzyn, Anna, Oppenheimer, John, Madan, Juliette C., Garnaat, Sarah L., Bernstein, Jonathan A., and Shaker, Marcus S.

Published
2024
Full Text
View/download PDF

12. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology

Author

Lieberman, Jay A., Chu, Derek K., Ahmed, Tasnuva, Dribin, Timothy E., Abrams, Elissa M., Anagnostou, Aikaterini, Blumenthal, Kimberly G., Boguniewicz, Mark, Chase, Nicole M., Golden, David B.K., Hartog, Nicholas L., Heimall, Jennifer R., Ho, Tina, Lawrence, Monica G., Khan, David A., Minniear, Timothy Dean, Mustafa, S. Shahzad, Oppenheimer, John J., Phillips, Elizabeth J., Ramsey, Allison, Rider, Nicholas L., Schneider, Lynda, Shaker, Marcus S., Spergel, Jonathan M., Stone, Cosby A., Jr, Stukus, David R., Wang, Julie, and Greenhawt, Matthew J.

Published
2024
Full Text
View/download PDF

13. Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent

Author

Mack, Douglas P., Dribin, Timothy E., Turner, Paul J., Wasserman, Richard L., Hanna, Mariam A., Shaker, Marcus, Tang, Mimi L.K., Rodríguez del Río, Pablo, Sobolewski, Brad, Abrams, Elissa M., Anagnostou, Aikaterini, Arasi, Stefania, Bajowala, Sakina, Bégin, Philippe, Cameron, Scott B., Chan, Edmond S., Chinthrajah, Sharon, Clark, Andrew T., Detjen, Paul, du Toit, George, Ebisawa, Motohiro, Elizur, Arnon, Factor, Jeffrey M., Greiwe, Justin, O’B Hourihane, Jonathan, Hughes, Sarah W., Jones, Douglas H., Muraro, Antonella, Nowak-Wegrzyn, Anna, Patel, Nandinee B., Scurlock, Amy M., Shah, Atul N., Sindher, Sayantani B., Tilles, Stephen, Vickery, Brian P., Wang, Julie, Windom, Hugh H., and Greenhawt, Matthew

Published
2024
Full Text
View/download PDF

18. Food Allergy, Nutrition, Psychology, and Health

Author

Gupta, Elena, Conway, Alexandra E., Verdi, Marylee, Groetch, Marion, Anagnostou, Aikaterini, Abrams, Elissa M., Nowak-Wegrzyn, Anna, Bukstein, Don, Madan, Juliette C., Hand, Matthew, Garnaat, Sarah L., and Shaker, Marcus S.

Published
2024
Full Text
View/download PDF

19. Teamwork in Clinical Medicine

Author

Shaker, Marcus S., Oppenheimer, John, Verdi, Marylee, Anagnostou, Aikaterini, Abrams, Elissa M., Blatman, Karen Hsu, Hand, Matthew, Spergel, Jonathan M., and Lang, David M.

Published
2024
Full Text
View/download PDF

27. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials

Author

Assa'ad, Amal H., Bernstein, David I., Bird, J. Andrew, Carr, Tara F., Carr, Warner W., Cheema, Amarjit S., Corren, Jonathan, Darter, Amy Liebl, Dorsey, Morna J., Fineman, Stanley M., Fleischer, David M., Fritz, Stephen B., Gogate, Shaila U., Greiner, Alexander N., Hampel, Frank C., Jr., Jacobs, Joshua S., Jain, Sanjeev, Jarvinen-Seppo, Kirsi, Jeong, David K., Johnston, Douglas T., Kachru, Rita, Kim, Edwin H., Koleilat, Majed, Lanser, Bruce J., Leonard, Stephanie A., Maier, Mary C., Manning, Michael E., Mansfield, Lyndon E., Matz, Jonathan, Nadeau, Kari, Ohayon, Jason A., Perez, Elena, Petroni, Daniel H., Pollard, Stephen J., Ponda, Punita, Portnoy, Jay M., Rachid, Rima, Ratner, Paul H., Robison, Rachel, Rupp, Ned T., Sanders, Georgiana M., Sharma, Hemant P., Sher, Ellen R., Sher, Lawrence D., Sher, Mandel, Shreffler, Wayne G., Siri, Dareen D., Skolnick, Helen S., Soong, Weily, Soteres, Daniel F., Spergel, Jonathan M., Stillerman, Allan, Sussman, Gordon L., Tam, Jonathan, Varshney, Pooja, Waserman, Susan, Windom, Hugh H., Wood, Robert, Yang, William H., Ciaccio, Christina, Goldsobel, Alan B., Anagnostou, Aikaterini, Beyer, Kirsten, Casale, Thomas B., Deschildre, Antoine, Fernández-Rivas, Montserrat, Hourihane, Jonathan O'B., Krawiec, Marta, Lieberman, Jay, Scurlock, Amy M., Vickery, Brian P., Smith, Alex, Tilles, Stephen A., Adelman, Daniel C., and Brown, Kari R.

Published
2022
Full Text
View/download PDF

28. GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management.

Author

Zuberbier, Torsten, Muraro, Antonella, Nurmatov, Ulugbek, Arasi, Stefania, Stevanovic, Katarina, Anagnostou, Aikaterini, Bonaguro, Roberta, Chinthrajah, Sharon, Lack, Gideon, Fiocchi, Alessandro, Le, Thuy‐My, Turner, Paul, Lozano, Montserrat Alvaro, Angier, Elizabeth, Barni, Simona, Bégin, Phillippe, Ballmer‐Weber, Barbara, Cardona, Victoria, Bindslev‐Jensen, Carsten, and Cianferoni, Antonella

Abstract

Immunoglobulin E (IgE)‐mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti‐IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE‐mediated food allergies by the US Food and Drug Administration (FDA). This GA2LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE‐mediated food allergies, based on a systematic review and meta‐analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE‐mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Use of Vaccines in Patients Receiving Dupilumab, A Systematic Review and Expert Delphi Consensus Recommendation: A position paper of the American College of Allergy, Asthma and Immunology

Author

Lieberman, Jay A, primary, Chu, Derek K, additional, Ahmed, Tasnuva, additional, Dribin, Timothy E, additional, Abrams, Elissa M, additional, Anagnostou, Aikaterini, additional, Blumenthal, Kimberly G, additional, Boguniewicz, Mark, additional, Chase, Nicole M, additional, Golden, David BK, additional, Hartog, Nicholas L, additional, Heimall, Jennifer R, additional, Ho, Tina, additional, Lawrence, Monica G, additional, Khan, David A, additional, Minniear, Timothy Dean, additional, Mustafa, S Shahzad, additional, Oppenheimer, John J, additional, Phillips, Elizabeth J, additional, Ramsey, Allison, additional, Rider, Nicholas L, additional, Schneider, Lynda, additional, Shaker, Marcus S, additional, Spergel, Jonathan M, additional, Stone, Cosby A, additional, Stukus, David R, additional, Wang, Julie, additional, and Greenhawt, Matthew J, additional

Published
2024
Full Text
View/download PDF

35. Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study

Author

Vickery, Brian P., Vereda, Andrea, Nilsson, Caroline, du Toit, George, Shreffler, Wayne G., Burks, A. Wesley, Jones, Stacie M., Fernández-Rivas, Montserrat, Blümchen, Katharina, O’B. Hourihane, Jonathan, Beyer, Kirsten, Anagnostou, Aikaterini, Assa’ad, Amal H., Ben-Shoshan, Moshe, Bird, J. Andrew, Carr, Tara F., Carr, Warner W., Casale, Thomas B., Chong, Hey Jin, Ciaccio, Christina E., Dorsey, Morna J., Fineman, Stanley M., Fritz, Stephen B., Greiner, Alexander N., Greos, Leon S., Hampel, Frank C., Jr., Ibáñez, Maria Dolores, Jeong, David K., Johnston, Douglas T., Kachru, Rita, Kim, Edwin H., Lanser, Bruce J., Leonard, Stephanie A., Maier, Mary C., Mansfield, Lyndon E., Muraro, Antonella, Ohayon, Jason A., Oude Elberink, Joanna N.G., Petroni, Daniel H., Pongracic, Jacqueline A., Portnoy, Jay M., Rachid, Rima, Rupp, Ned T., Sanders, Georgiana M., Sharma, Hemant P., Sharma, Vibha, Sher, Ellen R., Sher, Lawrence, Sindher, Sayantani B., Siri, Dareen, Spergel, Jonathan M., Sprikkelman, Aline B., Sussman, Gordon L., Tsoumani, Marina, Varshney, Pooja, Vitalpur, Girish, Wang, Julie, Yang, William H., Zubeldia, José Manuel, Smith, Alex, Ryan, Robert, and Adelman, Daniel C.

Published
2021
Full Text
View/download PDF

36. Development and acceptability of a decision‐aid for food allergy Oral immunotherapy in children.

Author

Anagnostou, Aikaterini, Abrams, Elissa M., Carver, Melanie, Chan, Edmond S., Eftekhari, Sanaz, Greiwe, Justin, Jaffee, Hannah, Lieberman, Jay A., Mack, Douglas P., Mustafa, S. Shahzad, Shaker, Marcus S., Stukus, David, Wang, Julie, and Greenhawt, Matthew

Subjects
*FOOD allergy, *PATIENT advocacy, *PATIENT compliance, *ALLERGENS, *IMMUNOTHERAPY
Abstract

Background Methods Results Conclusions Limited decision‐support tools are available to help shared decision‐making (SDM) regarding food oral immunotherapy (OIT) initiation. No current tool covers all foods, forms, and pediatric ages for which OIT is offered.In compliance with International Patient Decision Aid Standards criteria, this pediatric decision‐aid comparing OIT versus avoidance was developed in three stages. Nested qualitative data assessing OIT decisional needs were supplemented with evidence‐synthesis from the OIT literature to create the prototype decision‐aid content. This underwent iterative development with food allergy experts and patient advocacy stakeholders until unanimous consensus was reached regarding content, bias, readability, and utility in making a choice. Lastly, the tool underwent validated assessment of decisional acceptability, decisional conflict, and decisional self‐efficacy.The decision‐aid underwent 5 iterations, resulting in a 4‐page written aid (Flesch–Kincaid reading level 6.1) explaining therapy choices, risks and benefits, providing self‐rating for attribute importance for the options and self‐assessment regarding how adequate the information was in decision‐making. A total of n = 135 caregivers of food‐allergic children assessed the decision‐aid, noting good acceptability, high decisional self‐efficacy (mean score 85.9/100) and low decisional conflict (mean score 20.9/100). Information content was rated adequate and sufficient, the therapy choices wording balanced, and presented without bias for a “best choice.” Lower decisional conflict was associated with caregiver‐reported anaphylaxis.This first pediatric OIT decision‐aid, agnostic to product, allergen, and age has good acceptability, limited bias, and is associated with low decisional conflict and high decisional self‐efficacy. It supports SDM in navigating the decision to start OIT or continue allergen avoidance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Food sensitization and cardiovascular mortality: An intriguing association in need of further study

Author

Shaker, Marcus, primary, Abrams, Elissa M., additional, Oppenheimer, John, additional, Anagnostou, Aikaterini, additional, Codispoti, Christopher D., additional, Golden, David B.K., additional, Greenhawt, Matthew, additional, Stukus, David, additional, Moore- Clingenpeel, Melissa, additional, Hughes, Sarah W., additional, Mack, Douglas P., additional, Mustafa, S. Shahzad, additional, and Lang, David M., additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results